LONDON — An experimental CAR-T cell therapy has induced remission in several patients with severe, treatment-resistant lupus in early clinical trials, researchers reported this week.
The approach, which involves reprogramming a patient's immune cells to target problematic B cells, has shown promising results in small studies of people with systemic lupus erythematosus (SLE) who had not responded to standard treatments. Data presented at recent medical meetings, including updates around the EULAR European Congress of Rheumatology, highlighted cases of sustained remission.
In one early UK trial involving patients with severe lupus, five out of the first six treated remained in remission for more than 18 months, according to researchers. One patient experienced a flare after 11 months but showed overall improvement.
Broader reviews of CAR-T therapies targeting CD19, presented at the American College of Rheumatology Convergence in 2025, analyzed data from multiple studies involving around 145 patients. Those reviews indicated that a substantial portion achieved deep remission, with many able to discontinue other immunosuppressive medications.
Lupus, an autoimmune disease that can affect joints, skin, kidneys and other organs, currently has limited options for achieving long-term remission in refractory cases. Existing treatments often focus on managing symptoms and suppressing the immune system, but do not reset the underlying dysfunction.
"These early results are encouraging for patients with difficult-to-treat disease," said a researcher involved in one of the studies, speaking at a recent congress. Details on the exact protocols and patient selection criteria were presented in trial updates.
CAR-T cell therapy, originally developed for certain blood cancers, works by extracting T cells, genetically modifying them to attack CD19-expressing B cells — which play a key role in autoantibody production in lupus — and reinfusing them. Both autologous (patient's own cells) and allogeneic (donor-derived) versions have been tested.
Safety data from the early trials indicated manageable side effects, though larger studies are needed to assess long-term risks, researchers have noted. Not all patients responded uniformly, and some required monitoring for disease flares.
Multiple research groups and companies are advancing CAR-T programs for lupus. In May 2026, the Lupus Research Alliance and Genentech announced funding for studies aimed at better understanding the mechanisms behind the observed remissions and improving the approach.
As of June 2026, several Phase 1 and Phase 2 trials remain ongoing, with larger confirmatory studies planned. Exact timelines for potential regulatory submissions or broader availability remain unclear.
Clinicians emphasized that while the results represent a potential advance, the therapies are still investigational and not yet approved for routine use in lupus treatment. Patients interested in trials should consult specialists for eligibility details.
